Patterns of Atypical Antipsychotic Subtherapeutic Dosing Among Oregon Medicaid Patients

Oregon State University, Portland, USA.
The Journal of Clinical Psychiatry (Impact Factor: 5.5). 12/2008; 69(10):1540-7. DOI: 10.4088/JCP.v69n1003
Source: PubMed


To examine a cohort of Medicaid patients with new prescriptions for atypical antipsychotic medication to determine the prevalence of subtherapeutic atypical antipsychotic medication use and to identify patient and prescribing provider characteristics associated with occurrence of subtherapeutic use.
This observational cohort study examined Medicaid administrative claims data for patients aged 20 to 64 years with a new prescription for an atypical antipsychotic medication (clozapine, olanzapine, quetiapine, risperidone, ziprasidone) between January 1, 2004, and December 31, 2004. Patient diagnostic information was identified using the International Classification of Diseases, Ninth Revision, Clinical Modification codes on submitted medical claims. Patient characteristics, prescribing provider characteristics, length of therapy, and dosing were examined. A logistic regression assessed the probability of subtherapeutic dosing.
Among 830 individuals in our sample who began treatment with an atypical antipsychotic, only 15% had a documented diagnosis of schizophrenia, subtherapeutic dosing was common (up to 86% of patients taking quetiapine), and 40% continued less than 30 days with the index prescription. A logistic model indicated that a general practitioner as prescribing provider, length of therapy equal to or less than 30 days, and prescription of quetiapine were significantly associated with a subtherapeutic dose (p < .001, p = .028, and p < .001, respectively).
These results suggest that there is extensive use of expensive atypical antipsychotic medications for off-label purposes such as sedation or for other practice patterns that should be explored further. Approaches that minimize off-label atypical antipsychotic use could be of considerable value to Medicaid programs. In addition, these findings support the need for the introduction or increased use of utilization monitoring and the implementation of medication practice guidelines as appropriate decision support for prescribing providers.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The impingement of flame jets against cooled surfaces has widespread applications in areas ranging from pollution control to materials processing. Premixed flames are commonly employed to treat the surface of polymer films; the polymer is oxidized when briefly exposed to the products of combustion, thereby increasing polymer surface energy and improving wettability. In this study, the transport issues in this process were investigated using a pilot-scale treatment facility. Arrays of laminar premixed methane/air flame jets impinged upon a water-cooled rotating cylinder. Color bulls-eye Schlieren imaging and temperature measurements were used to experimentally investigate the flow field that develops between the hot products of combustion, the rotating cylinder, and the ambient environment. The effects of strain on the impinging flame-jet structure were modeled using the SPIN application of the CHEMKIN software. The temperature measurements and flow visualization suggest the source of non-homogeneous film surface treatment. To produce a uniform treatment zone, a significant separation distance between the burner and rotating cylinder is required to complete interjet mixing of gases prior to impingement. In addition, entrainment of ambient air at high roller-rotational speed results in an imbalance in the flow field that magnifies the problems caused by insufficient jet mixing. Chemical kinetics modeling reveals that the species that are likely to participate in surface oxidation are H, OH, O2, HO2, and H2O2. Atomic oxygen, previously considered important in polymer surface oxidation, is shown to be in low concentration (3 ppm) at the stagnation surface. Cold-wall quenching consumes atomic hydrogen, hydroxyl radicals, and atomic oxygen, while producing hydroperoxy radicals and hydrogen peroxide. The concentrations of these species at the stagnation surface correlate with improvements in wettability observed as a function of flame equivalence ratio.
    No preview · Article · Dec 2000 · Proceedings of the Combustion Institute
  • [Show abstract] [Hide abstract]
    ABSTRACT: PurposeThe prescription of psychotropic medications to children and adolescents has increased dramatically over the last decade. However, the development of disparities in prescribing is poorly understood. We examined whether clustering of utilization is a common phenomenon among early adopters of medications described the characteristics of clusters.Methods We obtained the complete Medicaid Analytic Extract (MAX) files for the State of Michigan between 1 January 2000 and 31 December 2003. We tracked the adoption of: aripiprazole, atomoxetine, escitalopram, methylphenidate OROS, and ziprasidone. We conducted retrospective, space-time analyses, scanning for clusters with high rates of prescribing. χ2 analyses were used to compare the attributes of patients living within clusters to patients living in the rest of the state for each medication. Clusters of utilization were identified via the spatial scan statistic. Analysis of variance (ANOVA) was then used to compare the numbers of mental health professionals per capita in geographic areas that did and did not demonstrate clustering of prescriptions for new psychotropic medications.ResultsAll five medications exhibited space-time clustering within the first 90 days following the US Food and Drug Administration (FDA) approval. The Medicaid population surrounding Kalamazoo was more likely to receive a prescription on multiple occasions. Excluding ziprasidone, clusters were not associated with greater geographic access to mental health care professionals.Conclusions Clustering of new prescriptions for psychotropic medications was a common phenomenon in this population. Surveillance and cluster identification allow the development of disparities to be studied. This information permits interventions to be targeted to locations prospectively. Copyright © 2009 John Wiley & Sons, Ltd.
    No preview · Article · Jul 2009 · Pharmacoepidemiology and Drug Safety
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Psychotropic medication polypharmacy is common in psychiatric outpatient settings and, in some patient groups, may have increased in recent years. To examine patterns and recent trends in psychotropic polypharmacy among visits to office-based psychiatrists. Annual data from the 1996-2006 cross-sectional National Ambulatory Medical Care Surveys were analyzed to examine patterns and trends in psychotropic polypharmacy within nationally representative samples of 13 079 visits to office-based psychiatrists. Office-based psychiatry practices in the United States. Outpatients with mental disorder diagnoses visiting office-based psychiatrists. Number of medications prescribed in each visit and specific medication combinations. There was an increase in the number of psychotropic medications prescribed across years; visits with 2 or more medications increased from 42.6% in 1996-1997 to 59.8% in 2005-2006; visits with 3 or more medications increased from 16.9% to 33.2% (both P < .001). The median number of medications prescribed in each visit increased from 1 in 1996-1997 to 2 in 2005-2006 (mean increase: 40.1%). The increasing trend of psychotropic polypharmacy was mostly similar across visits by different patient groups and persisted after controlling for background characteristics. Prescription for 2 or more antidepressants, antipsychotics, sedative-hypnotics, and antidepressant-antipsychotic combinations, but not other combinations, significantly increased across survey years. There was no increase in prescription of mood stabilizer combinations. In multivariate analyses, the odds of receiving 2 or more antidepressants were significantly associated with a diagnosis of major depression (odds ratio [OR], 3.44; 99% confidence interval [CI], 2.58-4.58); 2 or more antipsychotics, with schizophrenia (OR, 6.75; 99% CI, 3.52-12.92); 2 or more mood stabilizers, with bipolar disorder (OR, 15.46; 99% CI, 6.77-35.31); and 2 or more sedative-hypnotics, with anxiety disorders (OR, 2.13; 99% CI, 1.41-3.22). There has been a recent significant increase in polypharmacy involving antidepressant and antipsychotic medications. While some of these combinations are supported by clinical trials, many are of unproven efficacy. These trends put patients at increased risk of drug-drug interactions with uncertain gains for quality of care and clinical outcomes.
    Preview · Article · Jan 2010 · Archives of general psychiatry
Show more